logo-cellares
South San Francisco, US · Founded 2019 · Delaware corporation · 8 known investors
Cellares develops automated manufacturing systems and technology platforms to accelerate the production and commercialization of cell therapies. The company serves biopharmaceutical manufacturers and cell therapy developers worldwide.
Founders & leadership
Investors · 8
Reported raises · per SEC filings
Form D private placements▶$82MraisedMay 2021 · 9 investors · OtherRule 506(b)
▶$82MraisedMay 2021 · 9 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Justin ButlerDirector
- Fabian GerlinghausExecutive Officer, Director
- Victor TongDirector
- Omar KurdiExecutive Officer, Director
- Offering amount
- $82M
- Amount sold
- $82M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Cellares Grows Series D to $327 Million with $50 Million Prime Radiant Partners Investmentnatlawreview.com · 2026
- Cellares extends funding for cell therapy manufacturing - Drug Discovery World (DDW)ddw-online.com · 2026
- Cellares Raises $327M in Series D Fundingfinsmes.com · 2026
- Exclusive: Cellares raises $257M to fund global expansion as it eyes 2027 IPOendpoints.news · 2026
- Cellares Raises $257 Million Series D Led by BlackRock and Eclipse to Industrialize Global Cell Therapy Manufacturing with Breakthrough Automation - Cellarescellares.com · 2026
- Cell therapy manufacturing tech startup Cellares raises $82 million | Reutersreuters.com · 2021


